NEW YORK (GenomeWeb) – Invitae and Nanopharmacia today announced an exclusive partnership to provide access to Invitae's genetic tests for hereditary cancers in Mexico.
The deal also will make Invitae's tests available on a non-exclusive basis in Costa Rica and Panama. Financial and other terms were not disclosed.
Nanopharmacia, a provider of cancer molecular tests in Mexico and Latin America, will make Invitae's tests available to onco-geneticists and medical and surgical oncologists. Invitae offers single-gene BRCA1/2 testing, including full gene sequencing and deletion/duplication analysis, as well as a six-gene, high-risk hereditary breast cancer panel.
The San Francisco-based firm also offers an 18-gene women's hereditary cancer panel covering hereditary breast, ovarian, and endometrial cancer; a 29-gene hereditary cancer syndrome panel; a 17-gene hereditary pancreatic cancer panel; and other hereditary panels covering cancers including Lynch syndrome and colon cancers.